<p>强生（Johnson &amp; Johnson，NYSE:JNJ）的股价目标在周四的一份报告中被摩根士丹利的研究分析师从 167.00 美元上调至 169.00 美元，据 Benzinga 报道。该券商目前对该股票给予&#34;持平&#34;评级。摩根士丹利的股价目标指向股票当前价格的潜在上涨 7.93%。</p>
<p>获取 <strong>强生（Johnson &amp; Johnson）</strong> 的警报：</p>
<ul>
<li>这家医疗巨头的股票反弹：最低有 15% 的上涨空间</li>
</ul>
<p>其他几家研究机构也对 JNJ 发表了评论。美国银行在 4 月 17 日周三的一份研究报告中将强生（Johnson &amp; Johnson）的股价目标从 180.00 美元下调至 170.00 美元，并为该公司设定了&#34;中性&#34;评级。高盛集团在 5 月 30 日周四的一份研究报告中开始对强生（Johnson &amp; Johnson）进行覆盖。他们给予了&#34;中性&#34;评级，并为该公司设定了 160.00 美元的目标价。加拿大皇家银行在 6 月 17 日周一重申了对强生（Johnson &amp; Johnson）的&#34;跑赢市场&#34;评级，并为该公司设定了 175.00 美元的目标价。坎特菲茨杰拉德在 7 月 1 日周一的一份报告中重申了对强生（Johnson &amp; Johnson）的&#34;超配&#34;评级，并为该公司设定了 215.00 美元的目标价。最后，汇丰银行在 4 月 18 日周四的一份研究报告中将强生（Johnson &amp; Johnson）的评级从&#34;持有&#34;调升至&#34;买入&#34;，并将股票的目标价从 169.00 美元上调至 170.00 美元。共有八位投资分析师对该股票进行了持有评级，五位给予了买入评级，一位对该公司进行了强烈买入评级。根据 MarketBeat.com 的数据，该股目前的共识评级为&#34;中等买入&#34;，共识目标价为 174.21 美元。</p>
<p><strong>查看我们对强生（Johnson &amp; Johnson）的最新股票报告</strong></p>
<h2>强生（Johnson &amp; Johnson）股价上涨 3.7%</h2>
<ul>
<li>MarketBeat 周评 - 7/8 - 7/12</li>
</ul>
<p>周四，JNJ 股票开盘价为 156.58 美元。该公司的 50 天移动平均价格为 148.15 美元，200 天移动平均价格为 153.39 美元。强生（Johnson &amp; Johnson）的 52 周最低价为 143.13 美元，52 周最高价为 175.97 美元。该公司的资产负债比为 0.36，速动比率为 0.94，流动比率为 1.17。该公司的市值为 3768.4 亿美元，市盈率为 9.76，市盈增长比率为 2.54，贝塔系数为 0.52。</p>
<p>强生（Johnson &amp; Johnson，NYSE:JNJ）于 7 月 17 日周三公布了其季度收益结果。该公司每股盈利为 2.82 美元，超过分析师预期的 2.71 美元，超出 0.11 美元。强生（Johnson &amp; Johnson）的净利润率为 45.26%，净资产收益率为 36.70%。该公司在该季度实现了 224.5 亿美元的收入，超过分析师对 223.3 亿美元的预期。去年同期，该公司每股盈利为 2.80 美元。强生（Johnson &amp; Johnson）该季度的收入较去年同期增长了 4.3%。卖方分析师预计，强生（Johnson &amp; Johnson）本财年的每股盈利将达到 10.49 美元。</p>
<h2>对强生（Johnson &amp; Johnson）的对冲基金观点</h2>
<ul>
<li>AbbVie 股票：投资者购买的绝佳时机</li>
</ul>
<p>一些对冲基金最近对 JNJ 的持仓进行了调整。挪威中央银行在第四季度收购了约 4071.642 亿美元的强生（Johnson &amp; Johnson）股份。惠灵顿管理集团在第四季度将其对强生（Johnson &amp; Johnson）的持股增加了 16.4%。惠灵顿管理集团现在拥有 2401.9725 万股该公司股票，价值 3764.852 亿美元，较上一季度增加了 339.1657 万股。Price T Rowe Associates Inc. MD 在第一季度将其对强生（Johnson &amp; Johnson）的持股增加了 16.8%。Price T Rowe Associates Inc. MD 现在拥有 2183.4359 万股该公司股票，价值 3453.978 亿美元，较上一季度增加了 313.9499 万股。瑞典银行在第一季度收购了约 331.178 亿美元的强生（Johnson &amp; Johnson）股份。最后，国际资产投资管理有限责任公司在第四季度将其对强生（Johnson &amp; Johnson）的持股增加了 7875.8%。国际资产投资管理有限责任公司现在拥有 209.0384 万股该公司股票，价值 327.647 亿美元，较上一季度增加了 206.4175 万股。机构投资者和对冲基金拥有该公司股份的 69.55%。</p>
<h2>强生（Johnson &amp; Johnson）公司简介（获取免费报告）</h2>
<p>强生（Johnson &amp; Johnson）及其子公司在全球范围内从事医疗保健领域的各种产品的研究、开发、制造和销售。该公司的创新药物部门提供各种治疗领域的产品，包括免疫学，包括类风湿性关节炎、银屑病性关节炎、炎症性肠病和牛皮癣；传染病，包括 HIV/AIDS；神经科学，包括情绪障碍、神经退行性疾病和精神分裂症；肿瘤学，如前列腺癌、血液恶性肿瘤、肺癌和膀胱癌；心血管和代谢，包括血栓形成、糖尿病和黄斑变性；以及肺动脉高压，通过零售商、批发商、分销商、医院和医疗保健专业人士供处方使用。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五只股票比强生（Johnson &amp; Johnson）更好</li>
<li>如何找到被低估的股票</li>
<li>观察这 4 只超买股票，随着市场轮换的继续</li>
<li>TSX 创业交易所（前身为加拿大创业交易所）</li>
<li>芯片股：廉价购买还是潜在崩盘？</li>
<li>股票中的死亡交叉是什么？</li>
<li>黄金创新高：投资者应关注的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，这则报道已经经过 MarketBeat 编辑团队的审核。请将有关此报道的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ [紧急] 交易所利润中的另类币优选（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzU5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzU5"/></p>
<h2>现在是否值得投资$1,000 美元购买强生？</h2>
<p>在考虑是否投资强生之前，您需要听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票...而强生并不在名单上。</p>
<p>尽管强生目前在分析师中有一个&#34;持有&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

外服控股

强生

<p>摩根大通将强生的目标股价从 167 美元上调至 169 美元，并给予其"持平"评级。其他研究公司也对强生发表了不同的评级意见。该股开盘价为 156.58 美元，52 周最高价为 175.97 美元。强生报告季度每股收益为 2.82 美元，超过了预期。对强生股票持有空头头寸的对冲基金已经调整了其持仓。该公司及其子公司在全球范围内从事医疗保健产品的研究、开发、生产和销售</p>

<p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) had its price target increased by research analysts at Morgan Stanley from $167.00 to $169.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an &#34;equal weight&#34; rating on the stock. Morgan Stanley's price target points to a potential upside of 7.93% from the stock's current price.</p>
<div class="lb-trans"><p>强生（Johnson &amp; Johnson，NYSE:JNJ）的股价目标在周四的一份报告中被摩根士丹利的研究分析师从 167.00 美元上调至 169.00 美元，据 Benzinga 报道。该券商目前对该股票给予&#34;持平&#34;评级。摩根士丹利的股价目标指向股票当前价格的潜在上涨 7.93%。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<ul>
<li>This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum</li>
</ul>
<div class="lb-trans"><p>获取 <strong>强生（Johnson &amp; Johnson）</strong> 的警报：</p>
<ul>
<li>这家医疗巨头的股票反弹：最低有 15% 的上涨空间</li>
</ul>
</div><p>Several other research firms have also commented on JNJ. Bank of America dropped their price objective on shares of Johnson &amp; Johnson from $180.00 to $170.00 and set a &#34;neutral&#34; rating for the company in a research note on Wednesday, April 17th. The Goldman Sachs Group assumed coverage on Johnson &amp; Johnson in a research report on Thursday, May 30th. They set a &#34;neutral&#34; rating and a $160.00 target price for the company. Royal Bank of Canada reiterated an &#34;outperform&#34; rating and issued a $175.00 target price on shares of Johnson &amp; Johnson in a report on Monday, June 17th. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating and issued a $215.00 target price on shares of Johnson &amp; Johnson in a report on Monday, July 1st. Finally, HSBC upgraded Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating and boosted their price target for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Eight investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $174.21.</p>
<div class="lb-trans"><p>其他几家研究机构也对 JNJ 发表了评论。美国银行在 4 月 17 日周三的一份研究报告中将强生（Johnson &amp; Johnson）的股价目标从 180.00 美元下调至 170.00 美元，并为该公司设定了&#34;中性&#34;评级。高盛集团在 5 月 30 日周四的一份研究报告中开始对强生（Johnson &amp; Johnson）进行覆盖。他们给予了&#34;中性&#34;评级，并为该公司设定了 160.00 美元的目标价。加拿大皇家银行在 6 月 17 日周一重申了对强生（Johnson &amp; Johnson）的&#34;跑赢市场&#34;评级，并为该公司设定了 175.00 美元的目标价。坎特菲茨杰拉德在 7 月 1 日周一的一份报告中重申了对强生（Johnson &amp; Johnson）的&#34;超配&#34;评级，并为该公司设定了 215.00 美元的目标价。最后，汇丰银行在 4 月 18 日周四的一份研究报告中将强生（Johnson &amp; Johnson）的评级从&#34;持有&#34;调升至&#34;买入&#34;，并将股票的目标价从 169.00 美元上调至 170.00 美元。共有八位投资分析师对该股票进行了持有评级，五位给予了买入评级，一位对该公司进行了强烈买入评级。根据 MarketBeat.com 的数据，该股目前的共识评级为&#34;中等买入&#34;，共识目标价为 174.21 美元。</p>
</div><p><strong>View Our Latest Stock Report on Johnson &amp; Johnson</strong></p>
<div class="lb-trans"><p><strong>查看我们对强生（Johnson &amp; Johnson）的最新股票报告</strong></p>
</div><h2>Johnson &amp; Johnson Trading Up 3.7 %</h2>
<ul>
<li>MarketBeat Week in Review – 7/8 - 7/12</li>
</ul>
<div class="lb-trans"><h2>强生（Johnson &amp; Johnson）股价上涨 3.7%</h2>
<ul>
<li>MarketBeat 周评 - 7/8 - 7/12</li>
</ul>
</div><p>JNJ stock opened at $156.58 on Thursday. The firm has a fifty day moving average price of $148.15 and a 200 day moving average price of $153.39. Johnson &amp; Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $175.97. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The firm has a market cap of $376.84 billion, a PE ratio of 9.76, a price-to-earnings-growth ratio of 2.54 and a beta of 0.52.</p>
<div class="lb-trans"><p>周四，JNJ 股票开盘价为 156.58 美元。该公司的 50 天移动平均价格为 148.15 美元，200 天移动平均价格为 153.39 美元。强生（Johnson &amp; Johnson）的 52 周最低价为 143.13 美元，52 周最高价为 175.97 美元。该公司的资产负债比为 0.36，速动比率为 0.94，流动比率为 1.17。该公司的市值为 3768.4 亿美元，市盈率为 9.76，市盈增长比率为 2.54，贝塔系数为 0.52。</p>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating analysts' consensus estimates of $2.71 by $0.11. Johnson &amp; Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. During the same period last year, the firm posted $2.80 earnings per share. Johnson &amp; Johnson's revenue for the quarter was up 4.3% compared to the same quarter last year. Sell-side analysts anticipate that Johnson &amp; Johnson will post 10.49 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>强生（Johnson &amp; Johnson，NYSE:JNJ）于 7 月 17 日周三公布了其季度收益结果。该公司每股盈利为 2.82 美元，超过分析师预期的 2.71 美元，超出 0.11 美元。强生（Johnson &amp; Johnson）的净利润率为 45.26%，净资产收益率为 36.70%。该公司在该季度实现了 224.5 亿美元的收入，超过分析师对 223.3 亿美元的预期。去年同期，该公司每股盈利为 2.80 美元。强生（Johnson &amp; Johnson）该季度的收入较去年同期增长了 4.3%。卖方分析师预计，强生（Johnson &amp; Johnson）本财年的每股盈利将达到 10.49 美元。</p>
</div><h2>Hedge Funds Weigh In On Johnson &amp; Johnson</h2>
<ul>
<li>AbbVie Stock: A Perfect Dip for Investors to Buy</li>
</ul>
<div class="lb-trans"><h2>对强生（Johnson &amp; Johnson）的对冲基金观点</h2>
<ul>
<li>AbbVie 股票：投资者购买的绝佳时机</li>
</ul>
</div><p>A number of hedge funds have recently made changes to their positions in JNJ. Norges Bank acquired a new stake in shares of Johnson &amp; Johnson in the fourth quarter worth approximately $4,071,642,000. Wellington Management Group LLP boosted its stake in shares of Johnson &amp; Johnson by 16.4% in the fourth quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company's stock worth $3,764,852,000 after acquiring an additional 3,391,657 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Johnson &amp; Johnson by 16.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company's stock worth $3,453,978,000 after acquiring an additional 3,139,499 shares during the last quarter. Swedbank AB acquired a new stake in shares of Johnson &amp; Johnson in the first quarter worth approximately $331,178,000. Finally, International Assets Investment Management LLC grew its holdings in Johnson &amp; Johnson by 7,875.8% in the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company's stock valued at $327,647,000 after buying an additional 2,064,175 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近对 JNJ 的持仓进行了调整。挪威中央银行在第四季度收购了约 4071.642 亿美元的强生（Johnson &amp; Johnson）股份。惠灵顿管理集团在第四季度将其对强生（Johnson &amp; Johnson）的持股增加了 16.4%。惠灵顿管理集团现在拥有 2401.9725 万股该公司股票，价值 3764.852 亿美元，较上一季度增加了 339.1657 万股。Price T Rowe Associates Inc. MD 在第一季度将其对强生（Johnson &amp; Johnson）的持股增加了 16.8%。Price T Rowe Associates Inc. MD 现在拥有 2183.4359 万股该公司股票，价值 3453.978 亿美元，较上一季度增加了 313.9499 万股。瑞典银行在第一季度收购了约 331.178 亿美元的强生（Johnson &amp; Johnson）股份。最后，国际资产投资管理有限责任公司在第四季度将其对强生（Johnson &amp; Johnson）的持股增加了 7875.8%。国际资产投资管理有限责任公司现在拥有 209.0384 万股该公司股票，价值 327.647 亿美元，较上一季度增加了 206.4175 万股。机构投资者和对冲基金拥有该公司股份的 69.55%。</p>
</div><h2>Johnson &amp; Johnson Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>强生（Johnson &amp; Johnson）公司简介（获取免费报告）</h2>
</div><p>Johnson &amp; Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.</p>
<div class="lb-trans"><p>强生（Johnson &amp; Johnson）及其子公司在全球范围内从事医疗保健领域的各种产品的研究、开发、制造和销售。该公司的创新药物部门提供各种治疗领域的产品，包括免疫学，包括类风湿性关节炎、银屑病性关节炎、炎症性肠病和牛皮癣；传染病，包括 HIV/AIDS；神经科学，包括情绪障碍、神经退行性疾病和精神分裂症；肿瘤学，如前列腺癌、血液恶性肿瘤、肺癌和膀胱癌；心血管和代谢，包括血栓形成、糖尿病和黄斑变性；以及肺动脉高压，通过零售商、批发商、分销商、医院和医疗保健专业人士供处方使用。</p>
</div><h2>Further Reading</h2>
<ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>How to Find Undervalued Stocks</li>
<li>Watch These 4 Overbought Stocks As Market Rotation Continues</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>Chip Stocks: Bargain Buys or Looming Bust?</li>
<li>What is a Death Cross in Stocks?</li>
<li>Gold Hits New High: 3 Stocks Investors Should Watch</li>
</ul>
<div class="lb-trans"><h2>进一步阅读</h2>
<ul>
<li>我们喜欢的五只股票比强生（Johnson &amp; Johnson）更好</li>
<li>如何找到被低估的股票</li>
<li>观察这 4 只超买股票，随着市场轮换的继续</li>
<li>TSX 创业交易所（前身为加拿大创业交易所）</li>
<li>芯片股：廉价购买还是潜在崩盘？</li>
<li>股票中的死亡交叉是什么？</li>
<li>黄金创新高：投资者应关注的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，这则报道已经经过 MarketBeat 编辑团队的审核。请将有关此报道的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ [URGENT] Altcoin Winning Picks (From Crypto Swap Profits)(Ad)</p>
<div class="lb-trans"><p>→ [紧急] 交易所利润中的另类币优选（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NzU5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8759&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Johnson &amp; Johnson right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 美元购买强生？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑是否投资强生之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票...而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管强生目前在分析师中有一个&#34;持有&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

摩根士丹利将强生（NYSE:JNJ）的目标价上调至 169.00 美元